Company Encyclopedia
View More
name
3SBIO
01530.HK
3SBio Inc., an investment holding company, develops, produces markets, and sells biopharmaceutical products in Mainland China and internationally. The company provides TPIAO, a recombinant human thrombopoietin to treat chemotherapy-induced thrombopenia and immune thrombocytopenia; and Cipterbin, an anti-HER2 monoclonal antibody for the treatment of advanced HER2-positive breast cancer and pan-HER2. It also offers Yisaipu, the receptor fusion tumor necrosis factor inhibitor; EPIAO and SEPO, an erythropoietin injection; Mandi-minoxidil, an OTC external medicine for treating hair loss; and SPARIN, an injectable low-molecular-weight heparin calcium. In addition, the company provides Remitch, a nalfuraphine hydrochloride orally disintegrating tablets; MN709, a minoxidil foam formulation for the treatment of androgenetic alopecia and alopecia areata; and other products in the areas of nephrology, hematology, oncology, auto-immune, ophthalmology, and dermatology and metabolism.
1.377 T
01530.HKMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
B
BiotechnologyIndustry
Industry Ranking3/52
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreA
    • ROE15.36%A
    • Profit Margin25.99%A
    • Gross Margin85.31%A
  • Growth ScoreB
    • Revenue YoY7.91%B
    • Net Profit YoY42.42%B
    • Total Assets YoY1.37%C
    • Net Assets YoY14.34%A
  • Cash ScoreC
    • Cash Flow Margin384.72%C
    • OCF YoY7.91%B
  • Operating ScoreC
    • Turnover0.38C
  • Debt ScoreA
    • Gearing Ratio20.51%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Pfizer Partner 3SBio To Raise $400 Million In Stock Sale

    3SBio, a Chinese partner of Pfizer, plans to raise approximately $400 million through a share placement, primarily for research and development. This follows a previous agreement in July where Pfizer invested $100 million in 3SBio, aiming to advance cancer medicines. The collaboration highlights continued U.S.-China ties in healthcare despite broader trade tensions, with 3SBio's shares soaring over 300% in the past year.

    Forbes·
    HK
    01530
    -0.47%
    Forbes·
    HK
    01530
    -0.47%

    China’s 3SBio seeks US$400 million in Hong Kong to boost drug pipeline

    3SBio, a Chinese drug maker, plans to raise US$401 million by selling a 4.14% stake in Hong Kong to fund clinical research and expand its drug portfolio globally. The share placement is priced at a 6.5% discount, with proceeds mainly for R&D. Morgan Stanley will coordinate the deal. 3SBio's shares fell 4.48% following the announcement. The fundraising follows the spin-off of its hair-loss brand Mandi, which is preparing for an IPO.

    南华早报·
    HK
    01530
    -0.47%
    南华早报·
    HK
    01530
    -0.47%

    HK-listed 3SBIO slips on discounted share sale

    3SBio Inc's shares dropped 5.4% to HK$29.98, marking the largest one-day percentage drop since November 21. The company plans to sell 105.17 million new shares at a 6.5% discount to raise HK$3.12 billion for clinical research in China and the US. Despite the drop, the stock is up 397% YTD, while the Hang Seng Biotech Index is up 80.1%.

    Reuters·
    HK
    01530
    -0.47%
    Reuters·
    HK
    01530
    -0.47%

    3SBio Seeks HK$3.12 Billion via Share Sale

    3SBio Seeks HK$3.12 Billion via Share Sale

    marketscreener·
    HK
    01530
    -0.47%
    marketscreener·
    HK
    01530
    -0.47%

    The Hang Seng Index opened up 155 points, Alibaba rose over 3%, Nio fell over 6%, and 3SBIO's share placement declined｜Hong Kong stock market opens

    The Hang Seng Index opened 155 points higher this morning, Alibaba rose over 3%, and Nio fell over 6%. The three major U.S. stock indices all fell on Monday, while the Golden Dragon Index rose 0.87%. Bitcoin rebounded to $86,604, and gold prices fell to $4,216. NVIDIA's investment in Synopsys stimulated a rise in stock prices. Several car companies announced their delivery data for November, with Nio's stock price dropping over 6%. 3SBIO's share placement was discounted by 6.5%

    Stheadline·
    US
    BABA
    -0.40%
    HK
    09988
    +0.39%
    SG
    NIO
    +0.98%
    Stheadline·
    US
    BABA
    -0.40%
    HK
    09988
    +0.39%
    SG
    NIO
    +0.98%
    Posts
    View More
    © 2025 Longbridge｜Disclaimer